SHIFTING THE PARADIGM
mimiX is a biomedical company based in Switzerland. Our proprietary tissue production technology – Sound Induced Morphogenesis – was developed as a result of 10+ years of research and development efforts.
Our lead product in development is in the area of personalized medicine – FastSkin®, an autologous tissue for complex wound care. Future areas of interest include: regenerative medicine (neuroscience, cardiovascular, orthopaedics), drug development, cellular agriculture (clean meat), process technology and performance materials.
We target strategic discovery partnerships through industry and academic alliances.
Board of Directors
Andrew Williamson
UK-based
UK-based
Medical technology
Roland Herzog
Swiss-based
Swiss-based
Technology transfer
Leti McManus, CFA
Swiss-based
Swiss-based
Small cap investment, banking, corporate strategy
Marc Thurner
Swiss-based
Swiss-based
mimiX founder & serial entrepreneur
William Pang
HK-based
HK-based
Investment banking
« mimiX’s platform combines all the advantages of classical bioprinting upgraded to a new dimension. It is the beginning of a new era of bio fabrication and will help solve humans greatest healthcare challenges »
Andrew Williamson - President Heraeus Medical
Leadership Team
Marc Thurner
CEO
Dominic Bright
Software Engineer
Andreas Scheidegger
CTO
Roman Sojic
Marketing Manager
Roman Amrein
R&D Manager
Thierry Rebetez
Simulation & Physics
Jobs
Key Investors
